Contraceptives
- Oral Contraceptives
- Reduced efficacy with: Phenytoin, phenobarbital, carbamazepine, oxcarbazepine, topiramate, lamotrigine
- CI: Thromboembolism, estrogen tumors, active liver disease, pregnancy, uterine bleeding
- Typical Use Effectiveness
- 1) 3-year Etonogestrel implant: 99.95%
- 2) Vasectomy: 99.85%
- 3) Levonorgestrel IUD: 99.8%
- 4) Female Sterilization: 99.5%
- 5) Copper-T IUD: 99.2%
- 6) DMPA: actual 94%, theoretical 99.8%
- 7) OCPs: actual 91%, theoretical 99%
- 8) Male Condoms: actual 82%, theoretical 98%
- 9) Female Condoms: actual 79%, theoretical 95%
- P450 induces, decrease efficacy
- Phenobarbital, phenytoin, rifampin
- Postpartum Contraception
- If \<1 month: Copper IUD or Progestin-only contraception due to risk of VTE and breastfeeding risk with Estrogen
- Age ≥35 and smoker ≥15cigs/day: No estrogen containing drugs
- Use DMPA
- Progestin Only (Subdermal Implant ≥ Pill)
- No increase in VTE risk, can be used during breastfeeding
- Thickens cervical mucus, thins endometrium, inhibits ovulation
- Suppression of ovulation occurs unpredictably and not in all cycles
- Must be taken within 3 hours every day
- Kept up to 3 years, decreases bleeding in 50%, amenorrhea in 20%
- Unscheduled bleeding is mcc of discontinuation
- Intravaginal Rings (NuvaRing)
- Inserted for 3 weeks, removed to allow bleeding
- Increased risk of DVT
- Release estrogen and progesterone
- CI: ≥35 and smoke ≥15 cigs/day
- Combined Oral Contraceptive
- Estrogen/Progestin Contraceptives
- Suppress ovulation via FSH/LH dampening (no surge)
- Inhibits ovulation
- Thickens cervical mucus, thins endometrium, alters uterus, fallopian tube motility
- Benefits: Endometrial and ovarian cancer risk reduction, menstrual regulation, hyperandrogenism treatment
- Suppression of ovulation occurs predictably
- Yaz and Yasmin
- Contain drospirenone (progestin w/aldosterone antagonist effect to help combat premenstrual bloating
- Risks: VTEs, Hypertension, Hepatic adenoma, stroke/MI, Cervical Cancer
- CI: ≥35 and smoke ≥15 cigs/day, Severe HTN (≥160/100), migraine w/aura, breast cancer, liver disease, multiple CVD RF
- Depot Medroxyprogesterone Acetate (DMPA)
- Progesterone only, every 3 months
- Suppresses pulsatile release of GnRH inhibiting ovulation, thickens cervical mucus, decreases motility of fallopian tube cilia, thins endometrium
- Good for Sickle cell disease (reduces crises), Epilepsy (intrinsic anticonvulsant)
- Bad for causing weight gain, unscheduled bleeding, mood changes
- Intrauterine Device
- Release copper or progesterone
- Most effective preventative measures
- 10 year Copper-T or 5-year Levonorgestrel-containing one
- Avoid copper if anemic or heavy menstrual bleeding
- CI: Abnormal uterine anatomy, cervical stenosis, leiomyoma, suspected pregnancy, PID in the past, Wilson disease
- SE: Small risk of abortion, uterine perforation, expulsion
- Subcutaneous Implant
- Etonogestrel (Nexplanon), slowly releases progesterone over 3 years
- SE: Irregular bleeding, especially in 1st 6 months
- Transdermal Contraceptive Patch
- CI: ≥35 and smoke ≥15 cigs/day
- Must be changed weekly, 99% effective, nothing to remember daily
- Not approved for women ≥200lbs, patch may fall off, Nausea, headache, weight gain, irregular bleeding, breast pain
- Tubal Ligation
- Emergency Contraception
- Copper (0-120)
- Ulipristal
- Progestin only (Levonorgestrel up to 72)
- Ethinyl Estradiol + Levonorgestrel (Yuzpe Regimen)
- 2 pills 12 hours apart within 72 hours
- Can be used up to 120 hours, reduced efficacy
- Oral Contraceptives